BHA, Acrylamide, and H. pylori: What Cancer Listings Mean

A preservative in a supplement capsule, the browning on a roasted potato, and a stomach infection can all appear on the same U.S. carcinogen list. That sounds like a reason to empty the pantry. It is actually a reason to read the categories carefully.

The National Toxicology Program's 15th Report on Carcinogens lists 256 substances or exposure circumstances. But the report identifies hazard: whether something can cause cancer under some conditions. It does not calculate your personal odds of cancer from a capsule, a cup of coffee, or a home-cooked meal.

That distinction separates useful precaution from ambient dread. Butylated hydroxyanisole (BHA) and acrylamide are "reasonably anticipated to be human carcinogens." Chronic Helicobacter pylori infection is a "known human carcinogen." Those labels do not carry the same human evidence, nor do they call for the same response.

BHA: a reasonable ingredient to avoid, not a demonstrated human cancer threat

BHA is a synthetic antioxidant added to foods and sometimes used as an inactive ingredient in supplements. It slows fat oxidation, which is useful for shelf life and less thrilling for anyone trying to decipher an ingredient panel before breakfast.

The NTP places BHA in its lower-confidence category because animal studies found tumors in the forestomach. That detail is more than laboratory trivia: humans do not have a forestomach. The anatomical mismatch was central to the agency's decision not to classify BHA as a known human carcinogen.

No large human epidemiological study has established that BHA at food-additive concentrations causes cancer. That leaves two honest conclusions. First, the animal evidence gives a rational basis for choosing a comparable BHA-free supplement when one is easy to find. Second, the evidence does not justify treating BHA in a capsule as a quantified or established human cancer risk.

This is a recurring problem with carcinogen lists. A substance can meet a hazard threshold because it produces tumors in a specific animal tissue under experimental conditions, while the relevance of that result to ordinary human exposure remains uncertain. The NTP report does not provide a human dose-response curve, a safe threshold, or a cancer-risk percentage for BHA in supplements.

Acrylamide: common exposure, unsettled cancer risk at dietary doses

Acrylamide forms during the Maillard reaction, the chemistry that browns carbohydrate-rich foods. Coffee, roasted nuts, baked goods, fried potatoes, and processed starchy snacks can all contribute. You do not need an industrial accident to encounter it; you need a toaster.

Human biomarker studies confirm that exposure is widespread. A 2025 cross-sectional study of U.S. women by Li et al. measured acrylamide-hemoglobin adducts and glycidamide-hemoglobin adducts, biomarkers that capture exposure and metabolism. The study found these biomarkers across the population studied. Glycidamide is genotoxic, so its detection establishes that humans metabolize acrylamide to a compound with DNA-damaging potential. It does not establish that typical dietary exposure causes cancer.

Another 2025 cross-sectional study in middle-to-late adulthood by Gan et al. estimated dietary acrylamide exposure at 0.02 to 1.53 micrograms per kilogram of body weight per day. Higher biomarker levels were associated with higher systemic inflammatory markers and lower serum alpha-klotho concentrations. The authors discussed NF-kB signaling and pro-inflammatory cytokines as a possible biological pathway.

Those findings are worth taking seriously, but they answer a narrow question. The study measured exposure and biomarkers at one point in time. It cannot show that acrylamide caused the inflammation marker pattern, that inflammation preceded the exposure, or that either measure predicts cancer in people eating ordinary diets. Alpha-klotho and inflammatory markers are surrogate endpoints, not cancer incidence.

The direct human cancer evidence in this group of sources is less alarming. In a prospective analysis from the NutriNet-Santé cohort, Bellicha et al. examined estimated dietary acrylamide intake and subsequent breast cancer incidence. The study found no statistically significant association. A prospective cancer-outcome study carries more weight for this question than a cross-sectional biomarker analysis because it measures the outcome people actually care about.

The null result is useful but incomplete. It concerns breast cancer, not every plausible cancer site. It also does not prove zero risk, and the broader epidemiological literature has been inconsistent. Still, it directly challenges the simple story that animal carcinogenicity at high doses translates cleanly into cancer from everyday browned foods.

Practical cooking changes should target peaks, not food fear

Acrylamide reduction makes sense as low-cost harm reduction: avoid routinely eating heavily browned starchy foods, favor gentler cooking temperatures when practical, and do not treat dark browning as a nutritional achievement. These choices reduce a measurable exposure without requiring anyone to ban coffee or regard every roasted vegetable as an oncology consult.

The evidence does not support anxiety-driven elimination of all foods that generate acrylamide. Dose and cooking method matter more than the mere presence of browning chemistry. An epidemiological review by Iwasaki et al. likewise notes that cancer risks from environmental chemical exposures in general populations are generally lower than risks in occupational settings, even though chronic low-level exposures are widespread.

H. pylori belongs in a different risk category

Chronic H. pylori infection is different in both evidence quality and actionability. The NTP classifies it as a known human carcinogen, based on sufficient human evidence. Its causal path is well characterized: persistent infection can drive chronic stomach inflammation and, in some people, progression toward gastric adenocarcinoma.

Unlike BHA or acrylamide, this is not mainly a question of shaving down a diffuse dietary exposure. It is an infection that can be tested for and treated. For someone focused on long-term risk reduction who has never been evaluated for H. pylori, discussing a noninvasive urea breath test or stool antigen test with a clinician is more consequential than obsessing over trace excipients.

That recommendation needs one boundary. The sources reviewed here do not establish whether every asymptomatic person should undergo screening, nor do they provide trial evidence on prophylactic eradication in every population. Individual risk depends on factors such as symptoms, family history, geography, and clinical context. The strong conclusion is narrower: a confirmed human carcinogen with an available testing pathway deserves more attention than two lower-tier hazard listings.

Genes may modify susceptibility, but they do not create a personalized risk score

Glutathione S-transferase genes help process several carcinogen metabolites. A 2025 systematic review by Karimi et al. found that GSTM1 and GSTT1 polymorphisms can modify associations between diet-related exposures and cancer risk in observational studies. People with null variants may handle some exposures differently.

That is biologically plausible, but it is not yet a clinical calculator for BHA or acrylamide. Observational studies face confounding, and the review does not quantify a reliable personal cancer-risk change at food-additive BHA levels or at typical acrylamide intake. A GST result may eventually refine risk discussions; it should not become a license for either complacency or dietary panic.

The useful hierarchy is simple: address confirmed, testable risks first; reduce avoidable exposures next; and reserve certainty for evidence that measures human cancer outcomes.

The verdict

Choose BHA-free supplements when that choice is easy, but do not mistake a precautionary animal-based listing for proof that a standard capsule causes cancer in humans. Reduce routine exposure to heavily browned starchy foods, while recognizing that current human evidence has not shown a statistically significant breast-cancer association with estimated dietary acrylamide intake. Give chronic H. pylori the most attention: it carries the stronger classification, the clearer human evidence, and a practical route to testing and treatment.

The point of a carcinogen list is to identify possible causes of cancer. The point of good risk reduction is to ask how much exposure exists, what human outcome data show, and whether there is a useful action to take.